Diagnostic utility of STAT6
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
19
08
2019
accepted:
11
11
2019
revised:
07
11
2019
pubmed:
12
12
2019
medline:
7
4
2021
entrez:
12
12
2019
Statut:
ppublish
Résumé
Although the distinction of classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma using morphology and immunostains is straightforward in most instances, occasional cases pose diagnostic challenge. We sought to determine the utility of the novel YE361 STAT6 rabbit monoclonal antibody in Hodgkin lymphoma and diagnostically challenging B- and T-cell non-Hodgkin lymphoma entities with Hodgkin-like features. Cases from seven institutions included: 57 classical Hodgkin lymphomas (31% EBV+), 34 nodular lymphocyte predominant Hodgkin lymphomas, 34 mimicking B- and T-cell non-Hodgkin lymphomas, and 7 reactive lymphoproliferations. After review of histology, STAT6
Identifiants
pubmed: 31822802
doi: 10.1038/s41379-019-0428-0
pii: S0893-3952(22)00862-6
pmc: PMC8191386
mid: NIHMS1699237
doi:
Substances chimiques
Biomarkers, Tumor
0
STAT6 Transcription Factor
0
STAT6 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
834-845Subventions
Organisme : Intramural NIH HHS
ID : Z01 SC000550
Pays : United States
Références
Portlock CS, Donnelly GB, Qin J, Straus D, Yahalom J, Zelenetz A, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol. 2004;125:701–8.
doi: 10.1111/j.1365-2141.2004.04964.x
Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. CD15-expressing nodular lymphocyte-predominant Hodgkin lymphoma. Histopathology. 2011;58:803–5.
doi: 10.1111/j.1365-2559.2011.03829.x
Huppmann AR, Nicolae A, Slack GW, Pittaluga S, Davies-Hill T, Ferry JA, et al. EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults. Am J Surg Pathol. 2014;38:316–24.
doi: 10.1097/PAS.0000000000000107
Dojcinov SD, Venkataraman G, Pittaluga S, Wlodarska I, Schrager JA, Raffeld M, et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood. 2011;117:4726–35.
doi: 10.1182/blood-2010-12-323238
Nam-Cha SH, Montes-Moreno S, Salcedo MT, Sanjuan J, Garcia JF, Piris MA. Lymphocyte-rich classical Hodgkin's lymphoma: distinctive tumor and microenvironment markers. Mod Pathol. 2009;22:1006–15.
doi: 10.1038/modpathol.2009.54
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.
doi: 10.1182/blood-2016-01-643569
Hartmann S, Goncharova O, Portyanko A, Sabattini E, Meinel J, Kuppers R, et al. CD30 expression in neoplastic T cells of follicular T cell lymphoma is a helpful diagnostic tool in the differential diagnosis of Hodgkin lymphoma. Mod Pathol. 2019;32:37–47.
doi: 10.1038/s41379-018-0108-5
Nicolae A, Pittaluga S, Venkataraman G, Vijnovich-Baron A, Xi L, Raffeld M, et al. Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. Am J Surg Pathol. 2013;37:816–26.
doi: 10.1097/PAS.0b013e3182785610
Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, Kapp U, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2001;97:250–5.
doi: 10.1182/blood.V97.1.250
Guiter C, Dusanter-Fourt I, Copie-Bergman C, Boulland ML, le Gouvello S, Gaulard P, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004;104:543–9.
doi: 10.1182/blood-2003-10-3545
Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99:618–26.
doi: 10.1182/blood.V99.2.618
Hartmann S, Martin-Subero JI, Gesk S, Husken J, Giefing M, Nagel I, et al. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica. 2008;93:1318–26.
doi: 10.3324/haematol.12875
Tiacci E, Ladewig E, Schiavoni G, Penson A, Fortini E, Pettirossi V, et al. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood. 2018;131:2454–65.
Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, et al. Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma. Blood. 2018;131:2413–25.
Mottok A, Renne C, Willenbrock K, Hansmann ML, Brauninger A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood. 2007;110:3387–90.
doi: 10.1182/blood-2007-03-082511
Kiyotani K, Park JH, Inoue H, Husain A, Olugbile S, Zewde M, et al. Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. Oncoimmunology. 2017;6:e1278330.
doi: 10.1080/2162402X.2016.1278330
Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–60.
doi: 10.1093/bioinformatics/btp324
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.
doi: 10.1093/nar/gkq603
Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45:D777–83.
doi: 10.1093/nar/gkw1121
Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. PLoS One. 2012;7:e46688.
doi: 10.1371/journal.pone.0046688
Hartmann S, Eichenauer DA, Plutschow A, Mottok A, Bob R, Koch K, et al. Histopathological features and their prognostic impact in nodular lymphocyte-predominant Hodgkin lymphoma–a matched pair analysis from the German Hodgkin Study Group (GHSG). Br J Haematol. 2014;167:238–42.
doi: 10.1111/bjh.12997
Song JY, Eberle FC, Xi L, Raffeld M, Rahma O, Wilson WH, et al. Coexisting and clonally identical classic Hodgkin lymphoma and nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol. 2011;35:767–72.
doi: 10.1097/PAS.0b013e3182147f91
O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002;109 Suppl:S121–31.
doi: 10.1016/S0092-8674(02)00701-8
Alinari L, Blum KA. How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant. Blood. 2016;127:287–95.
doi: 10.1182/blood-2015-10-671826
Traverse-Glehen A, Pittaluga S, Gaulard P, Sorbara L, Alonso MA, Raffeld M, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29:1411–21.
doi: 10.1097/01.pas.0000180856.74572.73
Eberle FC, Rodriguez-Canales J, Wei L, Hanson JC, Killian JK, Sun HW, et al. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica. 2011;96:558–66.
doi: 10.3324/haematol.2010.033167
Eberle FC, Salaverria I, Steidl C, Summers TA Jr., Pittaluga S, Neriah SB, et al. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Mod Pathol. 2011;24:1586–97.
doi: 10.1038/modpathol.2011.116
Hartmann S, Eichenauer DA, Plutschow A, Mottok A, Bob R, Koch K, et al. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013;122:4246–52. quiz 92
doi: 10.1182/blood-2013-07-515825
Kis LL, Gerasimcik N, Salamon D, Persson EK, Nagy N, Klein G, et al. STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma. Blood. 2011;117:165–74.
doi: 10.1182/blood-2010-01-265272
Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais JP, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood. 2009;114:1236–42.
doi: 10.1182/blood-2009-03-209759
Siddiqi IN, Friedman J, Barry-Holson KQ, Ma C, Thodima V, Kang I, et al. Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations. Mod Pathol. 2016;29:570–81.
doi: 10.1038/modpathol.2016.51
Natoli A, Lupertz R, Merz C, Muller WW, Kohler R, Krammer PH, et al. Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs. Int J Cancer. 2013;133:1945–54.
doi: 10.1002/ijc.28189
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl J Med. 2015;372:311–9.
doi: 10.1056/NEJMoa1411087
Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268–77.
doi: 10.1182/blood-2010-05-282780
Ju W, Zhang M, Wilson KM, Petrus MN, Bamford RN, Zhang X, et al. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. Proc Natl Acad Sci USA. 2016;113:1624–9.
doi: 10.1073/pnas.1524668113